Ovintiv (NYSE:OVV) 주식

Ovintiv

Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.

Large Cap

News

Movers

Trading Ideas

COKE

EQNR

FTAI

MBLY

RIVN

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주가가 17.45% 상승했다. 이는 회사가 2024년 4분기 및 전체 연도 생산 및 배송 수치를 발표한 후 발생한 일이다.

리비안, 모빌아이 및 Arm은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 30일-1월 3일)

Emerging Markets

BEKE

BGNE

FANG

FUTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

이들 10개 대형주는 지난주 가장 좋은 성과를 냈으며, 중국 경기를 위한 추가 부양책의 수혜를 입은 미국 상장 중국 주식이 대부분을 차지했다. 1. 후투 홀딩스(NASDAQ:FUTU)의 주식은 중국 경제를 위한 추가 경기 부양책이 주말에 발표된 후 49.37% 상승했다.

중국 주식이 주도 - 리 오토와 JD닷컴은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 30일-10월 4일)

Ovintiv Inc

WIIM

Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.

A. Preview of timsTOF Ultra 2 system with novel Athena Ion Processor (AIP):
- Improves protein group identification in single-cell proteomics (SCP) by 15%-20%, and peptide identifications in SCP by 20%-25%
-Advances immunopeptidomics with 15%-20% more immunopeptide identifications
B. Launch of DeutEx&#x2122; software for hydrogen-deuterium exchange (HDX-MS) analysis
C. OmniScape&#x2122; 2025b: a breakthrough in top-down protein sequencing software
D. Advances in ProteoScape&#x2122; and Glycoproteomics software capabilities
E. Advances in TwinScape&#x2122; for cloud-based, AI-enabled proteomics quality monitoring

BRKR

Bruker Unveils 4D-Proteomics Breakthrough At US HUPO: Enhanced Single-Cell and Immunopeptidomics With timsTOF Ultra 2 And Athena Ion Processor

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

Price Target

Reiteration

Analyst Ratings

XENE

HC Wainwright & Co. Reiterates Buy on Xenon Pharmaceuticals, Maintains $53 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

MCHP

Microchip Technology Launched MPLAB XC Unified Compiler Licenses For Its MPLAB XC8, XC16, XC-DSC and XC32 C Compilers

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=223dc3d3ec3a60d49aba12f490f75c5b">Laser Photonics Corporation</a> (LPC) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>), a leading global developer of industrial laser systems for cleaning and other material processing applications, in partnership with its sibling company Fonon Technologies, announced today the receipt of a second order for its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fonon.us%2Fproducts%2Fdefensetech-mrls-portable-finishing-laser-1020&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=DefenseTech+MRLS+Portable+Finishing+Laser&amp;index=3&amp;md5=223a07b9d89ac41eff38d88550ae268c">DefenseTech MRLS Portable Finishing Laser</a> (MF-1020) handheld cleaning system. This order was facilitated once again through their distribution partner, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fincrediblesupply.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Incredible+Supply+%26amp%3B+Logistics&amp;index=4&amp;md5=d2db227391448095ee4cf287ffd15f20">Incredible Supply &amp; Logistics</a> (ISL), an award-winning product distribution and third-party logistics (3PL) company.
The DTMF-1020 air-cooled handheld pulsed laser cleaning system, equipped with dual-axis technology, streamlines maintenance processes. This system will be utilized by the same Navy command in Virginia Beach that ordered the first unit.

Government

Regulations

LASE

Laser Photonics Secures Second Order for DefenseTech MRLS Laser Cleaning System

Earnings

ATCH

Reported Earlier, AtlasClear Holdings Q2 EPS $(1.11) Down From $2.22 YoY, Sales $2.75M

SOAR

Volato Announced Today That It Has Begun Bitcoin Mining Operations, Marking An Early But Significant Step In Its Broader Exploration Of Aviation-integrated Cryptocurrency Mining

Leerink Partners analyst Mike Kratky initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Outperform rating and announces Price Target of $28.

Initiation

BBNX

Leerink Partners Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $28

<ul>
<li>SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p&lt;0.001, mTOQ-4 total score, primary endpoint)</li>
<li>2-hour pain freedom for most attacks reported at least half the time by 47.9% of patients after SYMBRAVO versus 1.0% after oral CGRPs (p&lt;0.001)</li>
<li>24-hour or greater sustained pain relief after a single dose reported by 47.9% of patients after SYMBRAVO versus 16.7% after oral CGRPs (p&lt;0.001)</li>
<li>Ability to quickly return to normal activities reported by 51.0% of patients after SYMBRAVO versus 11.5% after oral CGRPs (p&lt;0.001)</li>
<li>SYMBRAVO improved quality of life compared to after oral CGRPs (p&lt;0.001, MSQ)</li>
</ul>

AXSM

Axsome Therapeutics Unveils SYMBRAVO Success In EMERGE Phase 3 Trial, Paving The Way For Enhanced Migraine Treatment For CGRP Inhibitor Non-Responders

PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
"These results far exceeded our expectations for splicing correction following a single dose of PGN-EDODM1. Mis-splicing is the underlying cause of DM1 pathology, and we believe the mean splicing correction observed at 28 days following a single dose of PGN-EDODM1 at 10 mg/kg in the FREEDOM clinical trial surpasses those reported to date in multi-dose clinical trials of up to nine months in duration in patients with DM1. We believe this is a strong indicator of our EDO technology's potential to deliver therapeutic oligonucleotides to the nucleus and PGN-EDODM1's potential to address the underlying cause of disease," said James McArthur, PhD, President and CEO of PepGen. "We believe these results provide initial validation of PGN-EDODM1's ability to selectively bind the pathogenic CUG-repeat DMPK RNA and we look forward to evaluating PGN-EDODM1 with more doses over longer time periods in our FREEDOM2-DM1 multiple ascending dose study. Based on these initial results, we aim to build on the significant correction of mis-splicing observed in this single-dose study to potentially provide improved functional benefit for patients who currently have no available approved therapeutic options."

PEPG

PepGen Reports Early Data From FREEDOM-DM1 Trial for Myotonic Dystrophy

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and maintains $190 price target.

BCPC

HC Wainwright & Co. Reiterates Buy on Balchem, Maintains $190 Price Target

B of A Securities analyst Peter Henderson maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $149 to $175.

B of A Securities Maintains Buy on Live Nation Entertainment, Raises Price Target to $175

Mr. Doogue's ascension to CEO comes after 27 years of rising through the leadership ranks at Allegro, during which time he enabled many of Allegro's disruptive technologies, originally as an engineer and later as a business leader. Immediately prior to this promotion, Mr. Doogue served as Allegro's Executive Vice President and its first Chief Technology Officer (CTO), leading technology development and worldwide operations, which includes manufacturing, procurement, and quality. Mr. Doogue also previously served as the Company's Senior Vice President of Technology and Products, which included direct oversight of each of the Company's business units. As a testament to his roots as an engineer and technology innovator, Mr. Doogue personally holds 75 semiconductor-related U.S. patents.

ALGM

Allegro MicroSystems Names Mike Doogue As Chief Executive Officer

B of A Securities analyst John Murphy downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Neutral to Underperform and lowers the price target from $13 to $10.

Downgrades

B of A Securities Downgrades Rivian Automotive to Underperform, Lowers Price Target to $10

IVVD

Invivyd Says FDA Declined Its Request To Expand Existing Emergency Use Authorization Of PEMGARDA To Include Treatment Of Mild-to-moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $185 price target.

NBIX

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

NKTR

Nektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes

Biotech

Guidance

Health Care

General

BCRX

Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has reportedly begun to cancel leases for a significant portion of its AI data center capacity in the United States, as per a recent report by TD Cowen.
What Happened: TD Cowen disclosed on Friday that Microsoft has nullified leases equivalent to &#8220;a couple of hundred megawatts&#8221; of capacity, <a href="https://www.bloomberg.com/news/articles/2025-02-24/microsoft-cancels-leases-for-ai-data-centers-analyst-says">Bloomberg</a> reported on Monday. Additionally, the tech giant has also ceased the conversion of so-called statements of qualifications, which usually lead to formal leases. This strategy is reminiscent of tactics previously employed by competitors like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) when they decided to reduce capital expenditure.
TD Cowen&#8217;s report also hints at Microsoft&#8217;s gradual retreat from data center construction and acquisition.&nbsp;The report indicates that Microsoft has let agreements totaling over a gigawatt at larger sites expire and has withdrawn from several deals, each involving approximately 100 megawatts.
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/43901332/biggest-cage-match-ever-mark-cuban-warns-of-a-coming-clash-says-musks-ai-implementation-will-directly-challenge-trumps-grip-on-control">&#8216;Biggest Cage Match Ever&#8217;—Mark Cuban Warns Of A Coming Clash, Says Musk&#8217;s AI Implementation Will Directly Challenge Trump&#8217;s Grip On Control</a>
Why It Matters: This development comes unexpectedly as in January, Microsoft announced its plans to invest around $80 billion in developing AI-powered data centers and deploying AI and cloud-based applications globally. Microsoft&#8217;s possible reduction in spending and data center construction sparks concerns about whether the company is becoming more cautious about future demand.
According to TD Cowen&#8217;s analysts, these changes may suggest that Microsoft is potentially facing an oversupply situation. They also speculated that Microsoft&#8217;s partnership with OpenAI could be shifting in ways that&nbsp;mean the software giant won&#8217;t need the same level of investments. The analysts, however, stated that they are awaiting more details on this.
In January,&nbsp;<a href="https://www.benzinga.com/25/01/42806852/microsoft-pauses-construction-on-33-billion-mount-pleasant-data-center-project-cites-technology-changes-and-design-re-evaluation">Microsoft paused construction</a>&nbsp;on parts of its ambitious data center project in Mount Pleasant, citing changes in technology and design re-evaluation. This move, coupled with the recent lease cancellations, could signal a shift in Microsoft&#8217;s data center strategy.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/02/43905646/nvidia-set-for-clear-beat-and-raise-special-as-ai-demand-surges-says-dan-ives">Nvidia Set For &#8216;Clear Beat And Raise Special&#8217; As AI Demand Surges, Says Dan Ives</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Markets

Tech

MSFT

Microsoft Pulls Plug On AI Data Center Leases, Says Analyst: Oversupply Situation Likely

Commodities

Press Releases

Ovintiv Renews Annual Share Buy-Back Program

Ovintiv to Host its Third Quarter 2024 Results Conference Call and Webcast on November 8, 2024

Ovintiv Reports Third Quarter 2024 Financial and Operating Results

Ovintiv Strengthens Portfolio with Core Oil-Rich Montney Asset Acquisition

PARAMOUNT RESOURCES LTD. ANNOUNCES $3.325 BILLION ASSET SALE

Real Estate

The Week in Canadian Press Releases: 10 Stories You Need to See

Ovintiv to Host its 2024 Fourth Quarter and Year-End Results Conference Call and Webcast on February 27, 2025

Ovintiv Announces Closing of Uinta Asset Sale

Ovintiv Names Terri King to Board of Directors

Ovintiv Announces Closing of Montney Asset Acquisition

TSX:OVV

TSX:POU

Antero Resources Corporation Common Stock

Antero Resources

Chord Energy

Civitas Resources

CNX Resources

ConocoPhillips

California Resources Corporation Common Stock

California Resources

Comstock Resources

Coterra Energy

Devon Energy

EOG Resources

Expand Energy

Diamondback Energy

Hess

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas

Matador Resources

Murphy Oil

Permian Resources Corporation Class A Common Stock

Permian Resources

Range Resources

Texas Pacific Land Corporation Common Stock

Texas Pacific Land

Venture Global, Inc. Class A common stock

Venture Global

Vista Energy S.A.B. de C.V. American Depositary Shares, each representing one series A share, with no par value

Vista Energy

Viper Energy, Inc. - Class A Common Stock

Viper Energy

Woodside Energy Group Limited American Depositary Shares, each representing one Ordinary Share

Comments

Ovintiv

뉴스

파트너 / 기고자

벤징가 글로벌